Reata Pharmaceuticals Announces 3Q 2022 Financial Results and an Update on Clinical Development Programs

Reata Pharmaceuticals Announcements
The FDA decision not to hold an Advisory Committee Meeting to discuss Reata Pharmaceuticals product Omaveloxolone for the treatment of Friedreich’s ataxia hints to good news about the approval of this product approval on  February 2023.  

The NDA for Omaveloxolone for Friedreich’s ataxia is under review.

A PDUFA Date is decided upon on February 28, 2023.

Recently, Reata Pharmaceuticals (This content is for paid subscribers.

Please click here to subscribe or here to log in.